Gain Therapeutics (GANX)
US Market

Gain Therapeutics (GANX) Income Statement


Gain Therapeutics Income Statement

Last quarter (Q3 2023), Gain Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Gain Therapeutics's net income was $-4.72M. See Gain Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 55.18K$ 140.11K$ 133.93K$ 28.88K$ 41.30K$ 20.61K
Cost of Revenue
Gross Profit
$ 55.18K$ 140.11K$ 164.99K---
Operating Expense
$ 13.34M$ 17.92M$ -13.99M$ 3.51M$ 2.14M$ 1.05M
Operating Income
$ -22.41M$ -17.78M$ -13.83M$ -3.48M$ -2.10M$ -1.03M
Net Non Operating Interest Income Expense
$ 235.93K$ 375.36K-$ 3.64K$ -20.54K$ -52.48K
Other Income Expense
---$ -96.48K$ -65.68K$ -14.96K
Pretax Income
$ -22.08M$ -17.50M$ -13.89M$ -3.57M$ -2.19M$ -1.10M
Tax Provision
$ 142.88K$ 92.98K$ 4.01K$ 5.39K$ 7.11K$ 9.78K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -22.22M$ -17.59M$ -13.89M$ -3.58M$ -2.19M$ -1.11M
Basic EPS
$ -1.81$ -1.48$ -1.37$ -0.61$ -0.37$ -0.19
Diluted EPS
$ -1.81$ -1.48$ -1.37$ -0.61$ -0.37$ -0.19
Basic Average Shares
$ 48.91M$ 11.88M$ 10.17M$ 5.86M$ 5.86M$ 5.86M
Diluted Average Shares
$ 48.91M$ 11.88M$ 10.17M$ 5.86M$ 5.86M$ 5.86M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 13.34M$ 17.92M$ -13.99M$ 3.51M$ 2.14M$ 1.05M
Net Income From Continuing And Discontinued Operation
$ -22.22M$ -17.59M$ -13.89M$ -3.58M$ -2.19M$ -1.11M
Normalized Income
$ -9.76M$ -13.82M-$ -3.51M$ -2.15M$ -1.09M
Interest Expense
$ -22.63M$ -17.87M$ -13.90M$ -3.48M$ -2.10M$ -1.03M
$ -22.55M$ -17.81M$ -13.88M$ -3.47M$ -2.10M$ -1.03M
Currency in USD

Gain Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis